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Several genetic studies in both mice and humans 
have suggested linkage between Fc γ receptors 
(FcγRs), clustered on chromosome 1q23-24, 
and SLE. There are three classes of FcγRs: 
FcγRI (CD64), FcγRII (CD32), and FγRIII 
(CD16) (for review see reference 1). CD64 is 
encoded by three genes in the human (IA, IB, 
and IC) with similar biological properties (2), 
whereas CD16 is encoded by two genes (IIIA 
and IIIB) with distinct biological properties. 
CD16A is an activating FcγR, whereas CD16B 
is a glycosyl-  phosphatidylinositol–  anchored 
protein expressed exclusively on neutrophils 
and is likely to function as a decoy receptor for 
immune complexes (3). CD32 comprises the 
most complex cluster of low-affi   nity FcγRs. It 
is encoded by three genes in humans (IIA, IIB, 
and IIC), all with considerably diff  erent biolog-
ical properties. Although these molecules share 
>95% sequence identity in their extracellular 
domains, which bind IgG immune complexes 
with low affi   nity, their intracytoplasmic do-
mains are diverse, transducing diff  erent signals 
on receptor cross-linking (3). FcγRIIA and -C
are unique to humans and are single-chain ac-
tivation receptors bearing an immunorecep-
tor tyrosine-based activation motif sequence 
in their intracytoplasmic domains. FcγRIIA 
is widely expressed, found on B cells, myeloid 
cells, granulocytes, and dendritic cells, whereas 
FcγRIIC is often found to contain in-frame 
termination codons, which suggests that it may 
be evolving into a pseudogene (4). In contrast, 
FcγRIIB, found on B cells, macrophages, den-
dritic cells, neutrophils, and mast cells, is con-
served between mouse and human and contains 
an immunorecptor tyrosine-based inhibition 
motif in its intracytoplasmic domain, thereby 
transducing an inhibitory signal on coligation 
to the B cell receptor (BCR) (5–7). This inhi-
bition is mediated through the recruitment of 
the inositol polyphosphate phosphatase, SHIP, 
to the tyrosine-phosphorylated immunorecp-
tor tyrosine-based inhibition motif sequence, 
leading to the hydrolysis of PIP3 and the re-
lease of PH domain–containing proteins, with 
subsequent abrogation of immunorecptor tyro-
sine-based activation motif–initiated activation 
signals (7, 8).
Amino acid substitutions in the activating 
FcγR genes—arginine (R) for histidine (H) at 
position 131 in FcγRIIA and phenylalanine (F) 
for valine (V) at position 158 in FcγRIIIA—
have resulted in functional polymorphisms of 
these FcγRs with decreased binding affi   nity for 
IgG immune complexes. Numerous clinical 
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studies have investigated the association between these pol-
ymorphisms and susceptibility to SLE, as well as specifi  c dis-
ease manifestations, and found strikingly disparate results. 
Studies in Brazilian, Korean, African-American, German, 
and Thai populations (9–13) have demonstrated substantial 
associations between the FcγRIIA R131H allele and disease 
susceptibility or nephritis, whereas studies in Dutch,   British, 
Greek, African-Caribbean, Spanish, Korean, Hispanic, and 
Korean populations (10, 12, 14–20) found no associations. 
Four studies in Dutch, Korean, and Caucasian populations 
(14, 18–20) demonstrated clear associations between the 
FcγRIIIA F158V polymorphism and disease susceptibility or 
nephritis, whereas an equal number of studies in   German, 
Korean, and African-American populations (10, 12, 21) 
found no such associations. The FcγRIIIB NA2 allele has 
been associated with susceptibility to SLE in a Thai popu-
lation (13), but fi  ve studies in German (12), Chinese (22), 
Spanish (23), and Dutch (14, 18) populations have failed to 
demonstrate an association. Several polymorphisms in the 
FcγRIIB gene have been identifi  ed, and one in particular, 
the I232T polymorphism, has been shown to associate with 
disease susceptibility in three studies in Asian populations (13, 
24, 25). One of these studies also demonstrated a clear cor-
relation of the I232T allele with nephritis (2, 4). Two stud-
ies in African-American and Caucasian populations (26, 27) 
failed to fi  nd any association between disease or nephritis and 
the I232T allele. The collective results of these studies have 
failed to provide a clear role of FcR polymorphisms in SLE 
susceptibility, though they do suggest a strong association 
with ethnicity.
In contrast to these results, studies in mouse models of 
SLE have demonstrated a clear association between the in-
hibitory FcγRIIB and disease susceptibility (28–31). Mice on 
the nonautoimmune C67BL/6 background develop sponta-
neous lupus when the gene for FcγRIIB is deleted (28), and 
several studies have demonstrated reduced FcγRIIB expres-
sion on activated B cells in autoimmune-susceptible strains 
of mice, resulting from a promoter polymorphism found in 
these strains (32, 33). Restoration of the level of FcγRIIB on 
these cells by retroviral transduction reverts the lupus pheno-
type of these susceptible strains (34). These results suggest that 
levels of expression of FcγRIIB may play a substantial role in 
lupus susceptibility. Quantitative assessment of FcγRIIB ex-
pression on specifi  c human cell populations has been limited 
by the lack of serological reagents capable of distinguishing 
among these highly homologous molecules. To address this 
issue, we have used a recently developed novel antibody to 
quantitate the level of FcγRIIB expression on B cells in nor-
mal and lupus populations. We also looked for clinical asso-
ciations with FcγRIIB expression in SLE patients and used 
a calcium fl  ux assay to determine functional consequences of 
alterations in FcγRIIB expression.
RESULTS
Anti-Fc𝗄RIIB staining
The monoclonal antibody 2B6 is specifi  c for FcγRIIB and 
distinguishes between FcγRIIA and FcγRIIB on both   native 
and transfected cells, as shown in Fig. 1. Chinese hamster ovary 
(CHO) cells transfected with either FcγRIIA or FcγRIIB 
(CD32A or CD32B, respectively) were analyzed by FACS 
using either 2B6 or the previously described IV.3   monoclonal 
Figure 1.  Specifi  city of antibodies for the human Fc receptors 
Fc𝗄RIIA and Fc𝗄RIIB. The human myeloid (THP-1), B cell (Raji), or CHO-
transfected cell lines (CD32A CHO-K1 and CD32B CHO-K1) were stained 
with the anti-RIIA monoclonal antibody IV.3 or the anti-RIIB monoclonal 
antibody 2B6. 2B6 detects only FcγRIIB on the surface of the Raji or 
CD32B CHO-K1 cell lines and is negative for THP-1 and CD32A CHO-K1, 
thus demonstrating its specifi  city. IV.3 preferentially detects IIA, although 
some cross-reactivity to IIB is seen on the transfected CD32B CHO-K1 cell 
line. Open graphs represent isotype control, and shaded graphs represent 
the specifi  c antibody.
Table I.  Baseline characteristics of all SLE patients
Characteristic n = 62 (%)
Age (yr) 39 ± 13
Sex
  Male    9 (14)
  Female  53 (86)
Race
  African American  33 (53)
 Othera  29 (47)
Disease duration (yr) 11 ± 9
Mean prednisone dose (mg) 13 ± 15
On DMARDsb     20 (32.3)
SLEDAI (mean) 3.2 ± 3.4
Baseline disease activity
  Renal       9 (14.5)
  Arthritis     2 (3.2)
  Mucocutaneous     4 (6.5)
  Alopecia       7 (11.3)
  CNS     (0)
  Hemolytic anemia     (0)
  Serositis     (0)
a90% were Hispanic.
bDMARDs are disease modifying agents that include azathioprine, 
cyclophosphamide, cellcept, and methotrexate.JEM VOL. 203, September 4, 2006  2159
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antibody (35). The 2B6 antibody showed FcγIIB specifi  city 
and only background staining on FcγIIA transfectants. The B 
cell lymphoma line Raji was clearly stained by 2B6, whereas 
the monocytic line THP-1 did not display appreciable binding 
to 2B6. 2B6 thus represents an FcγRIIB-specifi  c monoclonal 
antibody, capable of detecting the molecule on transfected 
cells as well as on B cell lines and native cells.
B cell expression of Fc𝗄RIIB in controls and SLE patients
B cells from 62 patients with SLE and 18 nonautoimmune 
individuals (control A; Tables I and II) were examined for 
expression of FcγRIIB. The control group was composed 
of healthy subjects of predominantly Asian and Caucasian 
descent. It has been shown in mouse studies that FcγRIIB 
expression changes with B cell maturation (32, 33); hence, 
naive, memory B cells and plasmablasts were all analyzed 
separately. There were no diff  erences seen in either the per-
centage of B cells in the peripheral blood or in the distribu-
tion of naive and memory cells of the two groups, though 
the variability was greater for both measurements in the pa-
tients with SLE (unpublished data). As has been previously 
reported (36), patients with SLE had a signifi  cantly higher 
percentage of plasmablasts than nonautoimmune individuals 
(P < 0.01; unpublished data).
In the analysis of the SLE and control A groups, FcγRIIB 
was expressed on >80% of all B cell subsets in both groups. 
As seen in Fig. 2 A, the level of expression of FcγRIIB, as re-
fl  ected by the level of mean fl  uorescent intensity (MFI) stain-
ing, was equivalent on the naive B cell population in both 
groups. In contrast, memory B cells from SLE patients had 
signifi  cantly lower surface expression of FcγRIIB than the 
normal controls (Fig. 2 B). This reduction in FcγRIIB ex-
pression results from a failure of SLE patients to up-regulate 
FcγRIIB expression as B cells become memory cells (Fig. 2). 
Nonautoimmune individuals displayed an increased level of 
FcγRIIB expression on memory cells (P < 0.01; Fig. 2 C), 
as has been demonstrated for mouse B cells. All of the con-
trol group demonstrated an increase in FcγRIIB expression 
as B cells progressed from the naive to the memory com-
partment, whereas only 34 out of 62 SLE patients displayed 
Figure 2.  Fc𝗄RIIB expression on naive and memory B cells. 
PBMCs were stained with antibodies to CD19, CD27, and either antibody 
to FcγRIIB (2B6) or a control IgG antibody followed by antibody to 
mouse IgG1. Naive B cells (A) were identifi  ed as CD19+, CD27−; and 
memory B cells (B) were identifi  ed as CD19+, CD27+. The graph shows 
MFI of FcγRIIB after subtracting the MFI of the control antibody. The 
comparison is between B cells of nonautoimmune individuals (control A) 
and lupus patients. There is no difference in expression on naive cells, 
but there is decreased expression of FcγRIIB on memory cells of SLE 
patients. (C) The expression of FcγRIIB is increased on normal memory 
B cells, whereas in SLE patients (D) there is no increase in FcγRIIB expres-
sion on memory cells. The horizontal lines divide the data into quartiles.
Table II.  Baseline characteristics of controls
Characteristic
Control A 
n = 18
Control B 
n = 38
Age 34 ± 6.0 36 ± 10.9
Sex
  Male  9 (50%) 1 (3%)
  Female  9 (50%) 37 (97%)
Race
  African American 1 (6%) 19 (50%)
  Hispanic 1 (6%) 16 (42%)
  Asian 10 (55%) 1 (3%)
  Caucasian   6 (33%) 2 (5%)
The control B group was recruited to examine the association of ethnicity and 
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up-  regulation of FcγRIIB on memory cells (Fig. 2, C and 
D), leading to a signifi  cant diff  erence between FcγRIIB ex-
pression on memory cells of nonautoimmune individuals and 
SLE patients (P < 0.001).
The level of FcγRIIB expression on plasmablasts from 
nonautoimmune individuals was similar to that found on na-
ive B cells (Fig. 3 A). In contrast, SLE patients down-regu-
lated FcγRIIB expression on plasmablasts to a level below 
that of naive B cells (Fig. 3 B). Thus, there was a signifi  cantly 
lower level of FcγRIIB expression on SLE plasmablasts than 
on nonautoimmune plasmablasts (P < 0.01).
A second control group of 38 nonautoimmune individ-
uals (control B; Table II), ethnically matched with the SLE 
patients, was recruited after the initial analysis as crossvalida-
tion and to further explore the association between FcγRIIB 
and ethnicity. In this control group, 50% were African Amer-
ican and almost 50% were Hispanic. Similar to the previous 
control group, 92% of these healthy controls demonstrated 
increased expression of FcγRIIB on memory B cells. Thus, 
whereas 95% of all control subjects displayed increased ex-
pression of FcγRIIB on memory B cells, only 58% of the 
lupus patients displayed the same increased expression (P < 
0.01; Fig. 4, A and B). 84% of the lupus patients showed 
decreased expression of FcγRIIB on plasmablasts compared 
with 23% of the controls (P < 0.01).
BCR-induced calcium (Ca2+) response in B cells 
with reduced Fc𝗄RIIB expression
The important role of FcγRIIB in control of B cell activation 
through inhibition of BCR signaling is well established. We 
sought to investigate whether FcγRIIB-mediated suppression 
of BCR-induced Ca2+ response is impaired in B cells with 
decreased expression of FcγRIIB. To address this issue, we 
analyzed Ca2+ infl  ux in memory B cells stimulated with either 
intact IgG or F(ab′) (2) fragments of anti-γ antibody. Cross-
linking the BCR with whole Ig should elicit a lower Ca2+ re-
sponse compared with cross-linking with F(ab′) (2), where 
there is no FcγRIIB ligation. Memory B cells comprise class-
switched IgG expressing B cells; therefore, we chose to use an 
anti-γ antibody for B cell stimulation. Eight out of nine SLE 
patients with increased FcγRIIB expression on memory B 
cells (MFI increased by >15%) demonstrated the expected 
pattern of reduced Ca2+ infl  ux in response to IgG stimulation 
compared with F(ab′) (2) fragment stimulation (Fig. 5), with 
a diminished fl  ux when whole Ig was used. In contrast, no 
apparent diff  erence between IgG- or F(ab′)-induced (2) Ca2+ 
infl  ux was observed in six out of seven studied patients who 
failed to up-regulate FcγRIIB on memory B cells (MFI 
Figure 3.  Plasmablasts of SLE patients have reduced expression of 
Fc𝗄RIIB. Naive B cells were identifi  ed as CD19+, CD27− and plasmablasts 
as CD19+, CD27++. Expression of FcγRIIB was determined by subtracting 
the MFI of the isotype control antibody from the MFI of the anti-FcγRIIB 
antibody. Nonautoimmune individuals (control A; A) have the same level 
of expression of FcγRIIB on naive B cells and plasmablasts, whereas lupus 
patients (B) have a decreased level of expression of FcγRIIB on plasma-
blasts. The horizontal lines divide the data into quartiles.
Figure 4.  Percent difference in MFI of Fc𝗄RIIB between naive 
and memory B cells. The percent change in MFI was calculated by sub-
tracting the MFI of FcγRIIB on naive B cells from the MFI of FcγRIIB on 
memory B cells and dividing by the MFI of FcγRIIB on naive B cells × 100. 
(A) The percent change in MFI in SLE patients. 42% have a negative per-
cent change in MFI of FcγRIIB as the naive B cells transition to memory 
B cells, which is consistent with down-regulation of this inhibitory 
receptor. In contrast, only 8% of ethnically matched healthy controls 
(control B; B) have a negative percent change in MFI as their B cells 
  transition to memory B cells.JEM VOL. 203, September 4, 2006  2161
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  decreased by >15%; P = 0.008). These data demonstrate a 
reverse correlation between levels of FcγRIIB expression and 
BCR-mediated activation of memory B cells in SLE patients. 
Reduced FcγRIIB expression on the surface of memory B 
cells results in increased BCR-mediated B cell activation.
Clinical correlations
Patients were divided into groups based on the magnitude 
of the percent change in the MFI of FcγRIIB expression 
between naive and memory B cells. Down-regulators had 
a percent change in MFI ≤−15, and up-regulators had a 
percent change in MFI ≥15. The values of −15 and 15 were 
chosen arbitrarily based on the distribution of percent change 
in MFI values for the SLE patients (Fig. 4 A). There were 
no signifi  cant diff  erences in terms of disease duration, dis-
ease   activity as measured by the SLE disease activity index 
(SLEDAI), use of immunosuppressive agents, anti–double-
stranded DNA (dsDNA) antibody titers, complement levels, 
or the presence of renal disease in patients that displayed nor-
mal or dysregulated FcγRIIB expression. Additionally, there 
were no signifi  cant diff  erences in SLEDAI scores between 
the groups 3 mo after the time of the analysis of peripheral 
blood B cells; thus, down-regulation of the FcγRIIB recep-
tor did not appear to be an early marker of disease fl  are.
There were statistically signifi  cant  diff   erences in racial 
distribution between the groups with high and low FcγRIIB 
expression (Table III). 69% of the patients that clearly down-
regulated FcγRIIB were African American compared with 
30% of the up-regulators (P = 0.037). Conversely, 48% of 
the non–African-American patients up-regulated FcγRIIB 
expression on memory B cells compared with 18% of the 
  African-American patients (P = 0.037). 55% of the African-
American patients down-regulated FcγRIIB expression on 
memory B cells compared with 27% of others (P = 0.032). 
The striking diff  erences in racial distribution between those 
with high and low expression suggests that the down-regula-
tion of FcγRIIB receptors on memory B cells may represent 
a genetic diff  erence: either a polymorphism in the gene en-
coding FcγRIIB or in the expression of some factor involved 
in FcγRIIB regulation.
FcγRIIB expression on B cells was assessed a second time 
in six patients. Three of the patients that initially displayed 
increased FcγRIIB expression on memory B cells continued 
to display receptor up-regulation despite a maximum de-
crease in SLEDAI of six points and a decrease in prednisone 
dose of 20 mg. The other three patients were initially in the 
group with a small change in MFI between naive and mem-
ory cells and remained in that group with small increases in 
SLEDAI score (maximum increase of four) and no change in 
steroid doses.
DISCUSSION
We have demonstrated that FcγRIIB expression is up-reg-
ulated on memory B cells in nonautoimmune individuals. 
Increased expression of this inhibitory receptor that binds 
IgG immune complexes on activated B cells provides a feed-
back inhibitory loop whereby antibody homeostasis can be 
maintained. In addition, recent studies in mouse models 
expressing anti-DNA antibodies have indicated that this in-
hibitory pathway appears to regulate the progression of naive 
B cells to somatically mutated and class-switched memory 
and plasma cells (37). In the presence of suffi   cient FcγRIIB 
expression, the anti-DNA response is limited to nonpatho-
genic, IgM autoantibodies (37). Absence of FcγRIIB leads 
to the accumulation of IgG anti-DNA autoantibodies and 
immune complex–triggered glomerulonephritis (29). These 
Figure 5.  Calcium fl  ux is altered in SLE patients who fail to up-
regulate FC𝗄RIIB. Representative intracytoplasmatic Ca2+ fl  ux in mem-
ory B lymphocytes stimulated with whole IgG (dashed line) or F(ab′)2 
fragments (continuous line) of anti-γ antibody gated on CD20 and CD27 
double-positive cells that correspond to a memory B cell population. 
B cells with up-regulated FcγRIIB expression demonstrate signifi  cantly 
decreased Ca2+ fl  ux in response to intact IgG compared with F(ab′)2 frag-
ments, whereas both stimulants produce nearly identical Ca2+ signals in 
B cells with low FcγRIIB expression (P = 0.008). These data demonstrate 
impaired FcγRIIB-mediated suppression of BCR-induced Ca2+ response in 
memory B cells that failed to up-regulate FcγRIIB.
Table III.  Baseline characteristics of SLE patients grouped by 
extreme up- or down-regulation of the FcγRIIB receptors on 
memory B cells
∆ MFI < −15 
(n = 13)
∆ MFI > 15 
(n = 20) p-value
Race
  African American 9 (69%) 6 (30%) 0.037
  Other 4 (31%) 14 (70%) 0.037
Disease duration (yr) 8.4 ± 6 12.8 ± 9.3 0.15
SLEDAI (mean) 3.7 ± 3.1 3.0 ± 3.7 0.552
Mean prednisone 
 dose  (mg)
19 ± 16 14.3 ± 16.5 0.422
On DMARDs 5 (39%)     6 (30%) 0.71
Mean anti-dsDNA 
 titer
62.9 ± 82.6 57.6 ± 123 0.893
Renal disease 
 (baseline)
3 (23%)     3 (15%) 0.659
Percent ∆ MFI was calculated by subtracting the MFI of FcγRIIB on naive B cells 
from the MFI of FcγRIIB on memory B cells and dividing by the MFI on naive B cells 
× 100. A negative percent ∆ MFI refl  ects down-regulation of the FcγRIIB receptors.2162   DYSREGULATION OF FCγRIIB ON MEMORY B CELLS IN SLE | Mackay et al.
studies demonstrate that FcγRIIB expression on activated 
B cells provides a peripheral checkpoint for the maintenance 
of self-tolerance and limits the progression of autoreactive 
B cells that escape central tolerance from becoming IgG-
  producing memory and plasma cells. Furthermore, a twofold 
increase in FcγRIIB expression can markedly reduce disease 
in spontaneously lupus-prone mice (34). Interestingly, our 
data demonstrated that nonautoimmune individuals had a 
mean expression of FcγRIIB on memory B cells that was 
 1.5-fold higher than that of SLE patients; the mean in-
crease in FcγRIIB expression on memory B cells compared 
with naive B cells in nonautoimmune individuals was an 
 1.5-fold increase, whereas there was no mean increase in 
SLE patients.
Previous studies of FcγRIIB in human subjects with 
SLE have focused on the presence of specifi  c transmembrane 
and promoter polymorphisms of FcγRIIB (232T,187T, and 
-386C-120A) (13, 24–27). The strong disease association be-
tween the 232T allele and SLE reported in Japanese (24), Thai 
(13), and Chinese (25) populations has been followed by an 
elegant study showing that the 232T allele does not partition 
to lipid rafts and therefore lacks functional inhibitory activ-
ity (38). In this study, the 232T polymorphism did not alter 
membrane expression of FcγRIIB. It has also been reported 
that SLE B cells demonstrate an increased intracellular Ca2+ 
infl  ux in response to BCR/FcγRIIB cross-linking compared 
with normal and disease controls (39). This presumably re-
fl  ects inadequate inhibitory signaling in the SLE B cells. We 
now show that reduced expression of FcγRIIB contributes to 
decreased FcγRIIB-mediated suppression of BCR-induced 
Ca2+ response in memory B cells of SLE patients. Paradoxi-
cally, Su et al. have reported the strong disease association 
in Caucasians of a “gain of function” polymorphism in the 
promoter region of FcγRIIB presumed to result in the in-
creased expression of FcγRIIB on B lymphocytes and mon-
ocytes, although this was not directly assayed (40). Although 
the role of this polymorphism is not clear, it is of interest that 
a presumed increase in expression of FcγRIIB is present in 
non–African-Americans patients, consistent with the data we 
report in this paper. Further studies are needed to investi-
gate whether the down-regulation of FcγRIIB on memory 
B cells and plasmablasts observed in our cohort is the result of 
one of the previously described genetic polymorphisms.
Autoimmune diseases refl   ect a breakdown of multiple 
checkpoints, both centrally and in the periphery, that nor-
mally prevent the emergence, expansion, and activation of 
autoreactive cells. In SLE, multiple susceptibility genes act 
in a cumulative, threshold-driven manner to breach these 
checkpoints, which results in clinical disease.   Understanding 
the molecular mechanisms that control these checkpoints 
is of primary importance in the design and implementation 
of rational strategies for therapeutic intervention. Evidence 
from mouse studies has established the role of the inhibitory 
FcγRIIB receptor in maintaining the tolerogenic state; per-
turbations in the expression of this gene can result in auto-
immunity and a lupus-like syndrome in susceptible genetic 
backgrounds. Conversely, restoring correct expression of 
FcγRIIB on B cells in lupus-prone mice has recently been 
demonstrated to prevent the expansion and accumulation of 
autoantibody-producing plasma cells (34). We now dem-
onstrate that SLE patients show a similar dysregulation of 
FcγRIIB expression on activated B cells that correlates with 
increased Ca2+ infl  ux after BCR cross-linking by intact IgG, 
thereby validating the observations made in mouse models.
It has been previously reported that B cells from SLE pa-
tients are hyperresponsive to antigen. Recent experiments by 
Nussenzweig et al. (41) have demonstrated a defect in cen-
tral tolerance in the selection of immature and transitional 
B cells in SLE patients, which is most consistent with de-
creased responsiveness to antigen. Indeed, in estradiol-treated 
mice and in CD100-defi  cient mice, reduced BCR signaling 
leads to the survival and activation of autoreactive B cells (42, 
43). In this study, we demonstrate a defect in SLE patients 
in the expression of an inhibitor receptor known to play a 
role in peripheral tolerance in antigen-activated B cells. To-
gether, these observations suggest a model in which B cell 
hyporesponsiveness early in B cell development permits the 
maturation of autoreactive B cells to immunocompetence. 
Subsequently, B cell hyperresponsiveness, mediated by inad-
equate expression of FcγRIIB, permits the unregulated ex-
pansion and diff  erentiation of activated autoreactive B cells 
and the production of pathogenic autoantibodies. This model 
suggests that novel treatment strategies might focus on pe-
ripheral checkpoints and FcγRIIB expression.
MATERIALS AND METHODS
Study subjects
The patient population was composed of 62 patients followed at the Monte-
fi  ore and Jacobi Medical Centers in New York, all of whom met the Ameri-
can College of Rheumatology 1982 revised criteria for SLE (44). The study 
was approved by the Committee for Clinical Investigations, and all subjects 
were provided written informed consent. Anticoagulated peripheral blood 
was drawn once in most subjects and repeated in 6 out of the 62 subjects. 
Demographic data, including age, sex, ethnicity, and disease duration, were 
collected from the medical record at the time of the blood draw. Data re-
garding medication use and disease activity (assessed using the SLEDAI), as 
well as measurements of hematological and immunological parameters in-
cluding anti-DNA antibodies, C3, C4, and urinalyses, were obtained at the 
time of the blood draw and 3 mo later. Normal control subjects were re-
cruited from healthy patients attending a gynecology clinic and employees in 
the clinics and laboratory. All control subjects also provided written in-
formed consent. There are two control groups. Control group A consisted 
of 18 healthy controls recruited from employees in the laboratory. 55% of 
this group was Asian, 33% was Caucasian, 6% was African American, and 6% 
was Hispanic. After the association between FcγRIIB down-regulation and 
African-American ethnicity was noted, control group B (with comparable 
ethnic backgrounds to the SLE patients) was recruited. One half of this 
group of 38 nonautoimmune controls was African American; most others 
were Hispanics. Subjects were excluded from the control groups if they had 
a fi  rst-degree relative with SLE or were taking corticosteroids or estrogens.
Mouse monoclonal antibodies directed against human 
Fc𝗄RIIB (CD32B)
The procedures used for characterizing the 2B6 anti-FcγRIIB antibody 
have been previously described completely (unpublished data). In brief, 
CD32A transgenic mice were immunized with a purifi  ed soluble protein 
containing the complete extracellular domain of CD32B. Splenocytes JEM VOL. 203, September 4, 2006  2163
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from immunized mice were fused with a myeloma line, and the hybrid-
omas were selected by ELISA for their diff  erential ability to bind the in-
hibitory and activating Fc receptors. 2B6 was one out of seven hybridomas 
that reacted with CD32B at high titers with no or marginal reactivity 
with CD32A.
B cell phenotyping
Anticoagulated blood was obtained in tubes containing anticoagulant-ci-
trate-dextrose. Red blood cells were lysed with Pharm Lyse (Becton Dick-
inson). Cells were incubated with the following antibodies: CD19-APC, 
CD27-PE (Caltag), anti-FcRIIB (as described in the previous paragraph), 
mouse IgG1 control antibody, and goat anti–mouse IgG1 (BD Biosciences). 
Flow cytometry for the SLE subjects and the control A group was per-
formed with a FACSCalibur (Becton Dickinson) and analyzed with soft-
ware (FlowJo version 4.5.8; Tree Star, Inc.) at the Albert Einstein College 
of Medicine. Flow cytometry for the control B group was performed with 
a FACSCalibur and analyzed with FlowJo software at Columbia University 
Medical Center.
Analysis of Ca2+ infl  ux
Cell preparation. PBMCs were isolated by density gradient centrifugation 
using Ficoll (GE Healthcare). PBMCs were resuspended as 107 cells/ml in 
phosphate-buff  ered saline containing 10% FBS (PBS/FBS 10%) and incu-
bated with Ca2+-binding dye 1-indo, AM (Invitrogen) at a fi  nal concentra-
tion of 2.5 μM for 40 min at 37° in the dark. Surface staining with anti-CD20 
FITC (BD Biosciences) and anti-CD27 PE (Caltag) monoclonal antibodies 
was used for identifi  cation of memory B cells. Stained PBMCs were resus-
pended in DMEM containing 10% FBS and stored at room temperature be-
fore analysis by fl  ow cytometry.
Measurement of Ca2+ infl  ux by fl  ow cytometry. After 10 min rest at 
37°C, 106 PBMCs in 200 μl complete DMEM were analyzed using a fl  ow 
cytometer (LSRII; BD Biosciences). A 355-nm, 20-mW UV laser (XCYTE 
CY-355-020; LightWave Electronics) was used for excitation of indo-1. 
  After the baseline intracellular Ca2+ level was recorded for 30 s, either whole 
IgG or F(ab)2 fragments of anti-γ antibody (Rockland Immunochemicals) 
were added in equimolar concentration (40 μg/ml and 27 μg/ml, respec-
tively). An increase in binding of cytosolic Ca2+ to indo-1 results in a change 
of the emission spectrum of indo-1 from  510 nm (free form) to  420 nm 
(bound to Ca2+ form). The mean fl  uorescence ratio of these two wave-
lengths represents calcium infl  ux and was recorded for a total of 3 min. Data 
was analyzed using software (FlowJo version 6.4; Tree Star, Inc.).
Statistical analysis
The principle analyses for comparisons of MFI staining of FcγRIIB on B 
cells were the two-tailed Mann-Whitney test for comparisons between con-
trols and SLE patients and the two-tailed Wilcoxon signed rank test for 
comparisons within the control and SLE groups. p-values for race were cal-
culated using a two-sided Pearson’s χ2 test, and p-values for renal disease and 
DMARD use were calculated using a two-sided Fisher’s exact test. Because 
the data were not normally distributed, p-values for disease duration, SLE-
DAI scores, mean prednisone dose, and mean anti-dsDNA titers were ob-
tained using the two-tailed Mann-Whitney test. Correlation of FcγRIIB 
expression on memory B cells with calcium infl  ux on stimulation was ana-
lyzed using a two-sided Fisher’s exact test.
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